Cabaletta Bio reports smaller-than-expected Q3 loss

Reuters11-10

<a href="https://laohu8.com/S/CABA">Cabaletta Bio</a> reports smaller-than-expected Q3 loss

Overview

Company advancing rese-cel clinical trials with promising data for autoimmune diseases
Cabaletta expects cash reserves to fund operations into the second half of 2026

Outlook

Cabaletta plans BLA submission for rese-cel in 2027
Company expects FDA alignment on cohort designs by end of 2025
Cabaletta anticipates enrollment in registrational cohorts in 2026

Result Drivers

Research and development expenses were $39.8 million for the three months ended September 30, 2025, compared to $26.3 million for the same period in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income	Beat	-$44.87 mln	-$45.55 mln (6 Analysts)
Q3 Income from Operations		-$46.59 mln
Q3 Operating Expenses		$46.59 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cabaletta Bio Inc is $14.50, about 82.4% above its November 7 closing price of $2.55

Press Release: ID:nGNX527bsD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582876489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582876489","market":"fut","top_or_hot":-1,"title":"Cabaletta Bio reports smaller-than-expected Q3 loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> reports smaller-than-expected Q3 loss</title></head><body><p><span>Overview</span></p><ul><li><p>Company advancing rese-cel clinical trials with promising data for autoimmune diseases</p></li><li><p>Cabaletta expects cash reserves to fund operations into the second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Cabaletta plans BLA submission for rese-cel in 2027</p></li><li><p>Company expects FDA alignment on cohort designs by end of 2025</p></li><li><p>Cabaletta anticipates enrollment in registrational cohorts in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $39.8 million for the three months ended September 30, 2025, compared to $26.3 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$44.87 mln</p></td><td><p>-$45.55 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$46.59 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$46.59 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Cabaletta Bio Inc is $14.50, about 82.4% above its November 7 closing price of $2.55</p></li></ul><p>Press Release: <span>ID:nGNX527bsD</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cabaletta Bio reports smaller-than-expected Q3 loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCabaletta Bio reports smaller-than-expected Q3 loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> reports smaller-than-expected Q3 loss</title></head><body><p><span>Overview</span></p><ul><li><p>Company advancing rese-cel clinical trials with promising data for autoimmune diseases</p></li><li><p>Cabaletta expects cash reserves to fund operations into the second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Cabaletta plans BLA submission for rese-cel in 2027</p></li><li><p>Company expects FDA alignment on cohort designs by end of 2025</p></li><li><p>Cabaletta anticipates enrollment in registrational cohorts in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $39.8 million for the three months ended September 30, 2025, compared to $26.3 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$44.87 mln</p></td><td><p>-$45.55 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$46.59 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$46.59 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Cabaletta Bio Inc is $14.50, about 82.4% above its November 7 closing price of $2.55</p></li></ul><p>Press Release: <span>ID:nGNX527bsD</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0FG:1","article_id":"2582876489","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582876489","pubTimestamp":1762778548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cabaletta Bio reports smaller-than-expected Q3 lossOverviewCompany advancing rese-cel clinical trials with promising data for autoimmune diseasesCabaletta expects cash reserves to fund operations into","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CABA":"Cabaletta Bio"},"translate_title":"Cabaletta Bio报告第三季度亏损小于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CABA":0.9},"content_text":"Cabaletta Bio reports smaller-than-expected Q3 lossOverviewCompany advancing rese-cel clinical trials with promising data for autoimmune diseasesCabaletta expects cash reserves to fund operations into the second half of 2026OutlookCabaletta plans BLA submission for rese-cel in 2027Company expects FDA alignment on cohort designs by end of 2025Cabaletta anticipates enrollment in registrational cohorts in 2026Result DriversResearch and development expenses were $39.8 million for the three months ended September 30, 2025, compared to $26.3 million for the same period in 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net IncomeBeat-$44.87 mln-$45.55 mln (6 Analysts)Q3 Income from Operations-$46.59 mlnQ3 Operating Expenses$46.59 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Cabaletta Bio Inc is $14.50, about 82.4% above its November 7 closing price of $2.55Press Release: ID:nGNX527bsDFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582876489","isCrawlerRequest":true}